Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Foghorn Therapeutics's total assets was $190.95M at Sep 30, 2026. For fiscal 2025 it was $198.10M, down 30.2% from the year before. The highest annual figure on record is $519.77M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.10M | -30.2% |
| FY2024 | Dec 31, 2024 | $283.98M | -0.7% |
| FY2023 | Dec 31, 2023 | $285.92M | -29.4% |
| FY2022 | Dec 31, 2022 | $404.88M | -22.1% |
| FY2021 | Dec 31, 2021 | $519.77M | +103.4% |
| FY2020 | Dec 31, 2020 | $255.59M | +1044.0% |
| FY2019 | Dec 31, 2019 | $22.34M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $190.95M | -6.8% |
| Q2 FY2026 | Jun 30, 2026 | $203.39M | -10.1% |
| Q1 FY2026 | Mar 31, 2026 | $222.17M | -14.1% |
| Q4 FY2025 | Dec 31, 2025 | $198.10M | -30.2% |
| Q3 FY2025 | Sep 30, 2025 | $204.96M | -33.5% |
| Q2 FY2025 | Jun 30, 2025 | $226.24M | -31.1% |
| Q1 FY2025 | Mar 31, 2025 | $258.69M | +1.4% |
| Q4 FY2024 | Dec 31, 2024 | $283.98M | -0.7% |
| Q3 FY2024 | Sep 30, 2024 | $308.37M | -1.6% |
| Q2 FY2024 | Jun 30, 2024 | $328.59M | -3.2% |
| Q1 FY2024 | Mar 31, 2024 | $255.00M | -31.6% |
| Q4 FY2023 | Dec 31, 2023 | $285.92M | -29.4% |
| Q3 FY2023 | Sep 30, 2023 | $313.42M | -27.8% |
| Q2 FY2023 | Jun 30, 2023 | $339.58M | -25.7% |
| Q1 FY2023 | Mar 31, 2023 | $372.88M | -23.6% |
| Q4 FY2022 | Dec 31, 2022 | $404.88M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $433.93M | +133.2% |
| Q2 FY2022 | Jun 30, 2022 | $456.90M | +119.1% |
| Q1 FY2022 | Mar 31, 2022 | $488.31M | +112.4% |
| Q4 FY2021 | Dec 31, 2021 | $519.77M | +103.4% |
| Q3 FY2021 | Sep 30, 2021 | $186.07M | +30.6% |
| Q2 FY2021 | Jun 30, 2021 | $208.53M | +833.3% |
| Q1 FY2021 | Mar 31, 2021 | $229.89M | – |
| Q4 FY2020 | Dec 31, 2020 | $255.59M | – |
| Q3 FY2020 | Sep 30, 2020 | $142.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.34M | – |
See a number that looks wrong?